Image For Activity Cover
Analyzing the Pathophysiology of Obesity and its Impact on Individuals
Course Description
This six-part course explores the pathophysiology of body weight regulation along with the upstream factors that contribute to energy balance and influence weight management strategies. Individual modules address social determinants of obesity, lifestyle interventions, pharmacotherapy, surgical approaches, and strategies for long-term weight management. Throughout the modules, expert faculty cover the heterogeneity of disease, variability in treatment response, chronic disease management, and the impact of a patient's context.

Please review the course schedule below:
  • December 21, 2021: Launch of Modules 1-3
  • January 19, 2022: Launch of Modules 4-6
  • March 29, 2022: Live Q&A with all Faculty
This course was developed for full participation by learners. At least 5 modules will need to be completed in order to claim credit.
Target Audience
This course is appropriate for a wide range of care providers, especially those with little or no experience treating patients with obesity.
Learning Objectives
Upon completion of this course, learners will be able to:
  1. Discuss available and emerging therapeutic approaches to treat and manage obesity
  2. Evaluate the role of genetics and environmental factors in the rise of obesity amongst children and adults
  3. Analyze approaches to ensuring weight loss/maintenance and treatment adherence in overweight and obese patients
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.


Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

 

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 7.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsib
ility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org.

Faculty and Disclosures
  1. Speaker: Ellen Schur, MD, Director, Clinical Research Unit, UW Medicine Diabetes Institute Professor of Medicine, Division of General Internal Medicine
  2. Speaker: Kimberly Gudzune, MD, Associate Professor of Medicine John Hopkins Medicine
  3. Speaker: Jamy Ard, MD Professor of Epidemiology and Prevention Co-Director, Weight Management Center at Wake Forest Baptist Health
  4. Speaker: Dominica Rubino, MD, Washington Center for Weight Management and Research
  5. Speaker: Shaneeta Johnson, MD Director of the Minimally Invasive and Bariatric Surgery Program, and Residency Associate Program Director at Morehouse School of Medicine
  6. Speaker: Ania Jastreboff, MD Associate Professor Director of weight management and obesity prevention

 

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the ACCME, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's EBR faculty. There are no commercial supporters of this activity, and no commercial entities have had influence over the planning of this CME activity.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity regarding exposition or conclusion. 

The following faculty reported relevant financial relationships:

Kimberly Gudzune, Faculty American Board of Obesity Medicine, Medical Director, Eli Lilly, Advisory Board, Novo Nordisk, Grantee Eli Lilly - variety of products, services, licensing agreement with OSI; Novo Nordisk - various products and services. Conflict resolved by peer review to confirm the content is objective, evidence-based, and free of commercial bias.

Jamy Ard, Program Chair/Faculty Nestle Healthcare Nutrition, Consultant, Research support, Eli Lilly, Consultant, Research funding, Boehringer Ingelheim, Consultant, Research funding, Epitome Inc, Research funding, UnitedHealth Group R&D, Consultant, Research funding, KVKTech, Research support, WW, Research support, Novo Nordisk, Advisory board, Consultant Nestle - variety of products, services; Eli Lilly - variety of products, services, licensing agreement with OSI; BI - collaboration with Gubra to ID and validate target and innovative peptides for treatment of obesity; Epitome - self-administered treatment for overweight and obesity; UnitedHealth Group - weight loss program, JOIN for ME pediatric obesity program; KVKTech - prescription medicine for obesity; Novo Nordisk - various products and services. Conflicts resolved by peer review to confirm the content is objective, evidence-based, and free of commercial bias. 

Domenica Rubino, Faculty Novo Nordisk- Investigator (Institutional); Speaker; Consultant/Scientific Advisor; writing support; shareholder (private, independent of work with NN) Boehringer Ingelheim- Investigator (Institutional) Astra Zeneca- Investigator (Institutional) Obesinov, SARL- Investigator grant (Institutional) Medscape/WebMD- Honorarium Peer View- Honorarium Endocrine Society-Honorarium Novo Nordisk - various products and services, BI - collaboration with Gubra to ID and validate target and innovative peptides for treatment of obesity; Astra Zeneca - Partner with Regeron on weight loss, various products and services. Conflicts resolved by peer review to confirm the content is objective, evidence-based, and free of commercial bias. 

Shaneeta Johnson, Faculty Pfizer Advisory Board, Limited Pfizer - anti-obesity drugs. Conflict resolved by peer review to confirm the content is objective, evidence-based, and free of commercial bias. 

Ania Jastreboff, Faculty Novo Nordisk, Advisory Board/Consultant Eli Lilly, Advisory Board/Consultant Intellihealth, Consultant, stock options Boehringer Ingelheim, Consultant, Scholar Rock, Consultant, Pfizer, Advisory Board/Consultant, American Diabetes Association, Research Grant Support Novo Nordisk, Multi-Center Trial, Research Support Eli Lilly, Multi-Center Trial, Research Support NIH/NIDDK, Research Grant Support Spouse Disclosures: Elucidata, Advisory Board/Consultant, stock options Pangolin, Advisory Board/Consultant, stock options Agios, Advisory Board/Consultant, NIH/NIDDK, Research Grant Support Novo Nordisk - various products and services, Eli Lilly - variety of products, services, licensing agreement with OSI; Intellihealth - obesity treatment platform; BI - collaboration with Gubra to ID and validate target and innovative peptides for treatment of obesity; Pfizer - anti-obesity drugs; Eludicata - blood platelets and obesity. Conflict resolved by peer review to confirm the content is objective, evidence-based, and free of commercial bias. 

The following faculty reported no relevant financial relationships: Ellen Schur, MD, MS

The following peer reviewer reported no relevant financial relationships: Taraneh Soleymani, MD

The following Endocrine staff report no relevant financial relationships: Kristine Metter, CAE; Hannah Andrews, CAE; and Brandon Roccio. 


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grant from Novo Nordisk and Rhythm.

Summary
Availability: On-Demand
Available Dec 21, 2021 to Dec 31, 2022
Cost : FREE
Credit Offered:
7 AMA PRA Category 1 available
7 Participation available
Contains: 7 Courses
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By